While Materialise's Q1 results were mixed they exceeded low investor expectations, with the company's Medical segment continuing to excel. Market conditions are likely to remain challenging, but lower energy costs and increased defense spending in Europe could help to offset this. Materialise's Medical segment alone more than justifies its current market capitalization.
Materialise NV (NASDAQ:MTLS ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Harriet Fried - Alliance Advisors, IR Brigitte de Vet - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the First Quarter 2025 Materialise Financial Results Conference Call.
Materialise: Manufacturing Headwinds Are A Distraction
Materialise NV (NASDAQ:MTLS ) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Company Participants Harriet Fried - Investor Relations Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux Troy Jensen - Cantor Fitzgerald Operator Ladies and gentlemen thank you for standing by. Welcome to the Fourth Quarter 2024 Materialise Financial Results Conference Call.
Materialise (MTLS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Materialise (MTLS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Materialise (MTLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Materialise NV (NASDAQ:MTLS ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Harriet Fried - Investor Relations-Lippert/Heilshorn & Associates Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Alexander Kramer - Kepler Cheuvreux Jacob Stephan - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q3 2024 Materialise Financial Results Conference Call.
Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward.